Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo

Biochemical Pharmacology

Volumn 77, Issue 9, 2009, Pages 1506-1512

  Kim, Jie Wan ^a   Lee, Jun Ho ^a   Hwang, Bang Yeon ^b   Mun, Se Hwan ^a   Ko, Na Young ^a   Kim, Do Kyun ^a   Kim, Bokyung ^a   Kim, Hyung Sik ^c   Kim, Young Mi ^d   Choi, Wahn Soo ^a  

^a Konkuk University   (South Korea)

^b Chungbuk National University   (South Korea)

^c Pusan National University   (South Korea)

^d Duksung Women's University   (South Korea)

Author keywords

Allergy; Fyn kinase; IgE; Mast cells; Morin; Src family kinases

Indexed keywords

ANTIGEN; IMMUNOGLOBULIN E; INTERLEUKIN 4; LAT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MORIN; PROTEIN KINASE B; PROTEIN KINASE FYN; PROTEIN KINASE LYN; PROTEIN KINASE SYK; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; BONE MARROW; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; DRUG MECHANISM; IC 50; MALE; MAST CELL; MAST CELL LEUKEMIA; MOUSE; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; CELL DEGRANULATION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; MAST CELLS; MICE; MICE, INBRED BALB C; PASSIVE CUTANEOUS ANAPHYLAXIS; PROTEIN KINASE INHIBITORS; RATS; SRC-FAMILY KINASES;

EID: 63149152653     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.01.019     Document Type: Article

References (37)

1. Das D.K. Naturally occurring flavonoids: structure, chemistry, and high-performance liquid chromatography methods for separation and characterization. Methods Enzymol 234 (1994) 410-420
2. Wu T.W., Zeng L.H., Wu J., and Fung K.P. Morin: a wood pigment that protects three types of human cells in the cardiovascular system against oxyradical damage. Biochem Pharmacol 15 (1994) 1099-1103
3. Fang S.H., Hou Y.C., Chang W.C., Hsiu S.L., Chao P.D., and Chiang B.L. Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock. Life Sci 74 (2003) 743-756
4. Galvez J., Coelho G., Crespo M.E., Cruz T., Rodriguez-Cabezas M.E., Concha A., et al. Intestinal anti-inflammatory activity of morin on chronic experimental colitis in the rat. Aliment Pharmacol Ther 15 (2001) 2027-2039
5. Kitagawa S., Sakamoto H., and Tano H. Inhibitory effects of flavonoids on free radical-induced hemolysis and their oxidative effects on hemoglobin. Chem Pharm Bull 52 (2004) 999-1001
6. Wu T.W., Zeng L.H., Wu J., and Fung K.P. Morin hydrate is a plant-derived and antioxidant-based hepatoprotector. Life Sci 53 (1993) 213-218
7. Iwase Y., Takemura Y., Juichi M., Mukainaka T., Ichiishi E., Ito C., et al. Inhibitory effect of flavonoid derivatives on Epstein-Barr virus activation and two-stage carcinogenesis of skin tumors. Cancer Lett 173 (2001) 105-109
8. Lee S.F., and Lin J.K. Inhibitory effects of phytopolyphenols on TPA-induced transformation, PKC activation, and c-Jun expression in mouse fibroblast cells. Nutr Cancer 28 (1997) 177-183
9. Kempuraj D., Madhappan B., Christodoulou S., Boucher W., Cao J., Papadopoulou N., et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 145 (2005) 934-944
10. Shichijo M., Yamamoto N., Tsujishita H., Kimata M., Nagai H., and Kokubo T. Inhibition of syk activity and degranulation of human mast cells by flavonoids. Biol Pharm Bull 26 (2003) 1685-1690
11. Georas S.N., Guo J., De Fanis U., and Casolaro V. T-helper cell type-2 regulation in allergic disease. Eur Respir J 26 (2005) 1119-1137
12. Gould H.J., Sutton B.J., Beavil A.J., Beavil R.L., McCloskey N., Coker H.A., et al. The biology of IgE and the basis of allergic disease. Annu Rev Immunol 21 (2003) 579-628
13. Kraft S., and Kinet J.P. New developments in FcRI regulation, function and inhibition. Nature Rev Immunol 7 (2007) 365-378
14. Beaven M.A. Our perception of the mast cell from Paul Ehrlich to now. Eur J Immunol 39 (2009) 11-25
15. Rivera J., and Gilfillan A.M. Molecular regulation of mast cell activation. J Allergy Clin Immunol 117 (2006) 1214-1225
16. Holgate S.T., and Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 8 (2008) 218-230
17. Longui C.A. Glucocorticoid therapy: minimizing side effects. J Pediatr (Rio J) 83 (2007) 163-177
18. Bradding P. Novel approaches to the inhibition of mast cells in allergic disease. Clin Exp Allergy 38 (2008) 704-708
19. Meltzer E.O., Berkowitz R.B., and Grossbard E.B. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 115 (2005) 791-796
20. Lee J.H., Kim J.W., Ko N.Y., Mun S.H., Her E., Kim B.K., et al. Curcumin, a constituent of curry, suppresses IgE-mediated allergic response and mast cell activation at the level of Syk. J Allergy Clin Immunol 121 (2008) 1225-1231
21. Jensen B.M., Swindle E.J., Iwaki S., and Gilfillan A.M. Generation, isolation, and maintenance of rodent mast cells and mast cell lines. Curr Protoc Immunol 3 (2006) 3-23
22. 2+ and purified isozymes in washed permeabilized cells. J Biol Chem 268 (1993) 1749-1756
23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
24. Andrade M.V., Hiragun T., and Beaven M.A. Dexamethasone suppresses antigen-induced activation of phosphatidylinositol 3-kinase and downstream responses in mast cells. J Immunol 172 (2004) 7254-7262
25. Lorentz A., Klopp I., Gebhardt T., Manns M.P., and Bischoff S.C. Role of activator protein 1, nuclear factor-kB, and nuclear factor of activated T cells in IgE receptor-mediated cytokine expression in mature human mast cells. J Allergy Clin Immunol 111 (2003) 1062-1068
26. Frossi B., Rivera J., Hirsch E., and Pucillo C. Selective activation of Fyn/PI3K and p38 MAPK regulates IL-4 production in BMMC under nontoxic stress condition. J Immunol 178 (2007) 2549-2555
27. Asher M.I., Montefort S., Björkstén B., Lai C.K., Strachan D.P., Weiland S.K., et al. ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 26 (2006) 733-743
28. Masoli M., Fabian D., Holt S., and Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59 (2004) 469-478
29. Parravicini V., Gadina M., Kovarova M., Odom S., Gonzalez-Espinosa C., Furumoto Y., et al. Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat Immunol 3 (2002) 741-748
30. Yu M., Lowell C.A., Neel B.G., and Gu H. Scaffolding adapter Grb2-associated binder 2 requires Syk to transmit signals from FcepsilonRI. J Immunol 176 (2006) 2421-2429
31. Brown J.M., Wilson T.M., and Metcalfe D.D. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin Exp Allergy 38 (2008) 4-18
32. Wong B.R., Grossbard E.B., Payan D.G., and Masuda E.S. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13 (2004) 743-762
33. Rivera J., Fierro N.A., Olivera A., and Suzuki R. New insights on mast cell activation via the high affinity receptor for IgE. Adv Immunol 98 (2008) 85-120
34. Raso G.M., Meli R., Carlo G., Pacilio M., and Carlo R. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci 68 (2001) 921-931
35. Matsubara S., Li G., Takeda K., Loader J.E., Pine P., Masuda E.S., et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 173 (2006) 56-63
36. Yamamoto N., Takeshita K., Shichijo M., Kokubo T., Sato M., Nakashima K., et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c] pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 306 (2003) 1174-1181
37. Guyer B.J., Shimamoto S.R., Bradhurst A.L., Grossbard E.B., Dreskin S.C., and Nelson H.S. Mast cell inhibitor R112 is well tolerated and affects prostaglandin D2 but not other mediators, symptoms, or nasal volumes in a nasal challenge model of allergic rhinitis. Allergy Asthma Proc 27 (2006) 208-213